Early Lung Cancer Responds to Preoperative Nivolumab
COPENHAGEN—In a phase I study reported at the 2016 congress of the European Society for Medical Oncology (ESMO) six out of 15 patients with resectable early non-small cell lung cancer had “major pathological regression” to neo-adjuvant immunotherapy with nivolumab—the anti-PD1 …